Conference Abstracts
1. Storkel HL, Maekawa J, Aschenbrenner AJ. The effect of homonymy on learning correctly articulated versus misarticulated words. International Child Phonology Conference, Minneapolis, MN. June 2012
2. Aschenbrenner AJ, Balota DA, Tse CS, Yap MJ, Ratcliff, R. Lexical and semantic processing in healthy aging and early stage Alzheimer’s disease. Psychonomics. Minneapolis, MN. November 2012
3. Aschenbrenner AJ, Balota DA, Duchek J, Tse CS, Fagan A, Holtzman D, Ratcliff R. Healthy Aging and Early Stage AD: Examination of CSF biomarkers and RT distributions in a Category Verification Task. Cognitive Aging Conference, Atlanta, GA. April 2012
4. Davis CJ, Johnson RL, McCormick SF, McKague M, Kinoshita S, Bowers JS, Perry JR, Lupker SJ, Forster KI, Cortese MJ, Scaltritti M, Aschenbrenner AJ, Coane JH, White L, Yap MJ, Davis C, Kim J, Adelman JS. A behavioral database for masked form priming. Psychonomics, Toronto, Canada. November 2013
5. Aschenbrenner AJ, Balota DA. Revisiting the role of stimulus quality in models of cognitive processing. Psychonomics, Toronto, Canada. November, 2013
6. Yap MJ, Aschenbrenner AJ, Balota DA. Effects of Degradation, Frequency, and Priming: Do Trial History and Data Transformation Matter? Psychonomics, Toronto, Canada. November 2013
7. Aschenbrenner AJ, Balota DA. The Effects of Healthy Aging on Sequential Dependencies in the Stroop Task. Cognitive Aging Conference, Atlanta, Georgia. April, 2014
8. Aschenbrenner AJ, Balota DA, Tse CS, Fagan AM, Holtzman DM, Benzinger TLS, Morris JC. Synergistic and Mediational Effects of Alzheimer Disease Biomarkers on a Cognitive Measure. Alzheimer’s Association International Conference, Copenhagen, Denmark. July, 2014
9. Hassenstab J, Aschenbrenner AJ, Balota DA, Maue Dreyfus D, Bateman R, Morris JC, the Dominantly Inherited Alzheimer Network. Cognitive Performance in the Dominantly Inherited Alzheimer Network (DIAN): Baseline and Preliminary Longitudinal Findings. Alzheimer’s Association International Conference, Copenhagen, Denmark. July, 2014
10. Balota DA, Aschenbrenner AJ, Scaltritti M, Besner D. Exploring the first letter advantage in masked priming of a two alternative forced choice task. Psychonomics, Long Beach, California. November, 2014
11. Huff MJ, Balota DA, Aschenbrenner AJ, Duchek JM, Fagan AM, Holtzman DM, Benzinger TLS, Morris JC Task-switching errors show sensitivity to Alzheimer’s Disease Biomarkers. Alzheimer’s Association International Conference, Washington D.C. July, 2015
12. Aschenbrenner AJ, Balota DA, Duchek JM, Fagan AM, Holtzman DM, Morris JC. Cerebrospinal Fluid Biomarkers Predict Longitudinal Decline in Attentional Control in the Adult Children Study. Alzheimer’s Association International Conference, Washington D.C. July, 2015
13. Aschenbrenner AJ, Balota DA. Further explorations of the first letter advantage in two-alternative forced choice paradigms. Psychonomics, Chicago, IL. November, 2015
14. Millar PR, Balota DA, Maddox GB, Duchek JM, Aschenbrenner AJ, Jacoby LL, Fagan AM, Morris JC. Process dissociation estimates of Recollection are particularly sensitive to the earliest stages of Alzheimer disease and biomarkers in non-demented healthy control individuals. Cognitive Aging Conference, Atlanta, GA. April, 2016
15. Aschenbrenner AJ, Balota DA. Conflict adaptation in healthy aging. Cognitive Aging Conference, Atlanta, GA. April 2016
16. Hassenstab J, Aschenbrenner AJ, Balota DA, Lim YY, McDade E, Wang G, Xiong C, Bateman RJ, Morris JC, the Dominantly Inherited Alzheimer Network. Cognitive Trajectories in DIAN: Relationships with Symptom Onset, Mutation Types, and Clinical Status. Alzheimer Association International Conference, Toronto, Canada. July, 2016
17. Petros J, Hassenstab J, Snitz BE, Zhou Y, Ringman JM, McDade E, Wang G, Balota DA, Aschenbrenner AJ, Benzinger TLS, Cruchaga C, Fagan AM, Goate A, Holtzman DM, Bateman RJ, Morris JC, the Dominantly Inherited Alzheimer Network. Dynamic relationships between “big five” personality traits, Alzheimer disease biomarkers, and cognition in autosomal dominant Alzheimer disease. Alzheimer Association International Conference, Toronto, Canada. July, 2016
18. Aschenbrenner AJ, Balota DA. Dynamic adjustments of cognitive control in healthy aging. Psychonomics, Boston, MA. November, 2016)
19. Aschenbrenner AJ, Hassenstab J, Gordon BA, Benzinger TLS, Morris JC. Neuroimaging biomarkers of the A/T/N Classification system predict cross-sectional and longitudinal change in preclinical and early Alzheimer disease. Alzheimer Association International Conference, London, England. July, 2017
20. Hassenstab J, Aschenbrenner AJ, Sliwinski MJ, McDade E, Lim YY, Maruff P, Balota DA, Morris JC, Bateman RJ, for the Dominantly Inherited Alzheimer Network-Trials Unit. Rapid, Remote, and Repeatable: Smartphone-based “burst” cognitive assessments for global AD prevention trials. Clinical Trials in Alzheimer’s Disease, Boston, MA. November, 2017
21. Aschenbrenner AJ, Hassenstab J, McDade E, Wang G, Benzinger TLS, Bateman RJ, Morris JC. Cognitive run-in periods for Amyloid-positive enriched secondary prevention trials. Clinical Trials in Alzheimer’s Disease, Boston, MA. November, 2017
22. Huff MJ, Aschenbrenner AJ. Item-specific processing reduces false recognition in older and younger adults: Evidence from signal detection and the diffusion model. Psychonomics, Vancouver, British Columbia, Canada. November 2017
23. Wang G, Xiong C, McDade EM, Hassenstab J, Fagan AM, Benzinger TLS, Morris JC, Aschenbrenner AJ, Bateman RJ. A novel non-linear mixed effects model to estimate how the baseline value and the change in biomarkers simultaneously predict the change in cognition in dominantly inherited Alzheimer’s disease. Clinical Trials in Alzheimer’s Disease, Boston, MA. November, 2017
24. Jaeger J, Hagen C, Loft H, Lim YY, Aschenbrenner AJ, Segerdahl M, Tong G, Mielke M, Hassenstab J, Stricker N. The Early AD/ MCI Alzheimer’s Cognitive Composite (EMACC): Development and preliminary validation across four longitudinal cohorts of a cognitive endpoint for clinical trials in the MCI and Early AD stage of disease. Clinical Trials in Alzheimer Disease, Boston, MA. November 2017
25. Jaeger J, Hagen C, Loft H, Lim YY, Aschenbrenner AJ, Segerdahl M, Tong G, Mielke M, Hassenstab J, Stricker N. Cognitive Endpoints for Early Alzheimer’s Disease Trials: Development of the Early AD/MCI Alzheimer’s Cognitive Composite (EMACC). International Society for CNS Clinical Trials Methodology, Washington DC. February 2018
26. Gretz M, Huff MJ, Aschenbrenner AJ. Evaluating Item-Specific Processing Effects on False Recognition Using Signal Detection and Diffusion Modeling Analyses in Younger and Older Adults. Cognitive Aging Conference, Atlanta, GA. May 2018)
27. Aschenbrenner, A. J., Hassenstab, J., McDade, E., Wang, G., Lim, Y. Y., Morric, J. C., Bateman, R & the Dominantly Inherited Alzheimer Network. (June, 2018). Influence of mutation knowledge on clinical and cognitive outcomes in the Dominantly Inherited Alzheimer Network (DIAN). Australian Dementia Forum, Sydney, Australia.
28. Harrington KD, Maruff P, Masters CL, Aschenbrenner AJ, Fagan AM, Benzinger TLS….Hassenstab J. Examining the influence of undetected ATN neuropathology on cognitive aging trajectories. Alzheimer Association International Conference, Chicago, Illinois, USA. July, 2018
29. Wang G, Xiong C, McDade E, Li Y, Aschenbrenner AJ, Hassenstab J….Bateman RJ. A novel alternative model to MMRM as the primary model for sporadic AD clinical trials: The proportional MMRM. Alzheimer Association International Conference, Chicago, Illinois, USA. July, 2018
30. Li Y, Wang G, Xiong C, McDade E, Fagan AM, Gordon BA,…Aschenbrenner AJ,…Bateman RJ. A Statistical Method for Determining Biomarker Threshold for Alzheimer’s Disease. Alzheimer Association International Conference, Chicago, Illinois, USA. July, 2018
31. Wang G, Xiong C, McDade E, Li Y, Aschenbrenner AJ, Hassenstab J… Bateman RJ. Cross-sectional and longitudinal relationships among biomarkers for Dominantly Inherited Alzheimer’s Disease and its comparison with sporadic AD. Alzheimer Association International Conference, Chicago, Illinois, USA. July, 2018
32. Aschenbrenner AJ, Hassenstab J, Wang G, McDade E, Balota DA, Benzinger T LS….Bateman RJ Alzheimer disease biomarkers predict differences in personality: A cross-lagged panel analysis. Alzheimer Association International Conference, Chicago, Illinois, USA. July, 2018
33. Hassenstab J, Aschenbrenner AJ, Balota DA, McDade E, Lim YY, Fagan AM….Bateman RJ. Comparing Smartphone-Administered Cognitive Assessments with Conventional Tests and Biomarkers in Sporadic and Dominantly Inherited Alzheimer Disease. Alzheimer Association International Conference, Chicago, Illinois, USA. July 2018
34. Wang, G., Lorenzi, M., Li, Y., Donohue, M., McDade, E., Aschenbrenner, AJ., Benzinger, TLS,…Bateman, RJ. Estimating years from clinical symptom onset for sporadic Alzheimer disease: How far are we? Alzheimer Association International Conference, Los Angeles, California, USA. July 2019
35. Wang, G., Aschenbrenner, AJ., Li, Y., McDade, E., Liu, L., Bezinger, TLS, Bateman, RJ…Xiong, C. Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer disease. Alzheimer Association International Conference, Los Angeles, California, USA. July 2019
36. Dincer, A., Mehrotra, V., Aschenbrenner, AJ., McCullough, AA., Duchek, JM., Balota, DA….Gordan, BA. Preclinical AD pathology partially mediates the relationship between cortical thickness and attentional control. Alzheimer Association International Conference, Los Angeles, California, USA. July 2019
37. Dincer, A., Gordan, BA., Vlassenko, AG., Goyal, MS., Aschenbrenner, AJ., McCullough, AA….Benzinger, TLS. Comparisons of Alzheimer disease biomarker measures as predictors of cognition. Alzheimer Association International Conference, Los Angeles, California, USA. July 2019
38. Li, Y., Xiong, C., Aschenbrenner, AJ., Chang, C., Buckles, V., Moulder, K…Morris, JC. Item Response Theory Analysis of the Clinical Dementia Rating. Clinical Trials in Alzheimer Disease, San Diego, California, USA, December 2019.
39. Bateman, RJ., Aschenbrenner, AJ., Benzinger, TLS., Clifford, DB., Cruchaga, C., Fagan, AM., Farlow, M., Goate, A., Hassenstab, J., Jack, CR., Koeppe, R., McDade, E., Mills, S., Morris, JC., Salloway, S., Santacruz, A., Wang, G., Xiong, C., and the DIAN-TU study team. Results of the DIAN-TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD. ADPD, Vienna, Austria, April 2020.
40. Nicosia, J., Bangert, A., Hassenstab, J., Aschenbrenner, AJ., Balota, D. Keep up the pace: Declines in simple repetitive timing differentiates healthy aging from the earliest stages of Alzheimer’s disease. Cognitive Aging Conference, Atlanta, Georgia, USA, April 2020.
41. Bateman, RJ., Aschenbrenner, AJ., Benzinger, TLS., Clifford, DB., Cruchaga, C., Fagan, AM., Farlow, M., Goate, A., Hassenstab, J., Jack, CR., Koeppe, R., McDade, E., Mills, S., Morris, JC., Salloway, S., Santacruz, A., Snyder, P., Wang, G., Xiong, C., and the DIAN-TU study team. Results of the DIAN-TU prevention trial of solanezumab and gantenerumab. American Neurological Association Annual Meeting, Los Angles, California, USA, October 2020.